docetaxel anhydrous has been researched along with Hypersensitivity in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 3 (60.00) | 2.80 |
Authors | Studies |
---|---|
Banerji, A; Blumenthal, KG; Cogan, AS; McMahon, AE; Robinson, LB; Saff, RR; Wolfson, AR | 1 |
Ichikawa, G; Nakanishi, K; Okazaki, S; Suzuki, S | 1 |
Chen, L; Guo, X; Liu, H; Liu, J; Shi, Y; Tang, C; Zhao, Y; Zheng, X | 1 |
Chen, KR; Hayakawa, N; Honda, A; Ito, Y; Kosaka, T; Maeda, T; Nagata, H; Nakamura, S; Okata, U; Oya, M | 1 |
Anderson, CM; Barrett, B; Dorr, VJ; Lyss, AP; Malhotra, V; Perry, MC; Reynolds, M; Westgate, S | 1 |
1 review(s) available for docetaxel anhydrous and Hypersensitivity
Article | Year |
---|---|
Polysorbate 80 as a possible allergenic component in cross-allergy to docetaxel and fosaprepitant: A literature review.
Topics: Allergens; Docetaxel; Dyspnea; Humans; Hypersensitivity; Polysorbates | 2023 |
1 trial(s) available for docetaxel anhydrous and Hypersensitivity
Article | Year |
---|---|
Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Heart; Humans; Hypersensitivity; Kidney; Liver; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nerve Tissue; Neutropenia; Radiography; Taxoids; Treatment Outcome | 2004 |
3 other study(ies) available for docetaxel anhydrous and Hypersensitivity
Article | Year |
---|---|
COVID-19 vaccines tolerated in patients with paclitaxel and docetaxel allergy.
Topics: COVID-19; COVID-19 Vaccines; Docetaxel; Humans; Hypersensitivity; Paclitaxel; SARS-CoV-2 | 2022 |
Allergy testing for Cremophor in a patient with cervical cancer with infusion reactions to paclitaxel and docetaxel.
Topics: Docetaxel; Female; Humans; Hypersensitivity; Paclitaxel; Polyethylene Glycols; Taxoids; Uterine Cervical Neoplasms | 2022 |
Evaluation of histopathological findings at the injection site following degarelix administration.
Topics: Aged; Aged, 80 and over; Docetaxel; Drug Therapy, Combination; Erythema; Gonadotropin-Releasing Hormone; Hematologic Diseases; Humans; Hypersensitivity; Injections, Subcutaneous; Male; Middle Aged; Oligopeptides; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Risk Factors; Skin; Taxoids | 2015 |